The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Is there an optimal time to deploy immunotherapies in multiple myeloma?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Meral Beksaç, Ankara University School of Medicine, Ankara, TR, about immunotherapy for MM. We asked, Is there an optimal time to deploy immunotherapies in multiple myeloma?

Is there an optimal time to deploy immunotherapies in multiple myeloma?

In this video, Meral Beksaç talks about how the field of immunotherapy has been advancing rapidly in recent years, with novel monoclonal antibodies (mAbs), alone or with drug conjugates, being developed for use at diagnosis and relapse. Patients today can benefit from the use of anti-CD38 mAbs alongside chemotherapy, whether they are eligible for transplant or not. High rates of measurable residual disease negativity can be achieved by using these treatments.

Figure 1. New ESMO guidelines proposal for the treatment of relapsed multiple myeloma, presented by Meral Beksaç at EBMT 2020, courtesy of María-Victoria Mateos.1

Ab, antibody; CAR, chimeric antigen receptor; dara, daratumumab, dex, dexamethasone; IMiD, immunomodulatory imide drug; PI, proteasome inhibitor; pom, pomalidomide.

  1. Beksaç M. How should we position immunotherapies in the changing paradigm of myeloma treatment? 46th Annual Meeting of the EBMT; Sep 1, 2020; Virtual.

Share: